Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption

Nanoscale ◽  
2017 ◽  
Vol 9 (19) ◽  
pp. 6264-6277 ◽  
Author(s):  
Yi-pu Zhao ◽  
Wei-liang Ye ◽  
Dao-zhou Liu ◽  
Han Cui ◽  
Ying Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Resorption ◽  
Bone Metastases ◽  
Inhibit Bone Resorption ◽  
Bone Targeting ◽  
Treat Breast Cancer

scholarly journals Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis

2015 ◽  
Vol 26 (11) ◽  
pp. 2205-2213 ◽  
Author(s):  
M.F.K. Ibrahim ◽  
S. Mazzarello ◽  
R. Shorr ◽  
L. Vandermeer ◽  
C. Jacobs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Bone Metastases ◽  
Meta Analysis ◽  
Standard Of Care ◽  
Bone Targeting

Abstract 2198: Integrin αvβ3-targeted lipase-labile docetaxel-prodrug micelles preferentially treat breast cancer bone metastases

2016 ◽  
Author(s):  
Michael H. Ross ◽  
Alison K. Esser ◽  
Anne H. Schmieder ◽  
Grace Cui ◽  
Xiaoxia Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Integrin Αvβ3 ◽  
Treat Breast Cancer

Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption

2021 ◽  
pp. 1-6
Author(s):  
Francesco Pavese ◽  
Alessandro Parisi ◽  
Silvia Rotondaro ◽  
Valentina Cocciolone ◽  
Giovanni Pierorazio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Resorption ◽  
Bone Metastases ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Underlying Mechanism ◽  
Recurrence Risk ◽  
Disease Recurrence ◽  
Breast Cancer Patients ◽  
Mineral Density

BACKGROUND: Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20–45% of them will experience a disease recurrence, particularly bone metastases in 60–80% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. PATIENTS AND METHODS: In this single-institution cohort study, we performed a retrospective analysis of “luminal-like” EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). RESULTS: 143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45–65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25–54), while among patients who did not was 61 months (95%CI: 50–80) (HR = 1.45 [95%CI: 0.97–2.17], p = 0.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI: 1.06–2.42], p = 0.0244). Adjuvant Tamoxifen, adjuvant AIs/Tamoxifen and no-treatment did not revealed to be associated to TSkR. CONCLUSIONS: In this cohort of EBC patients with bone recurrence, AIs treatment seems to be related to a shorter TSkR. AIs-induced bone resorption might represent the underlying mechanism.

scholarly journals Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone

2021 ◽  
Author(s):  
Zeru Tian ◽  
Chenfei Yu ◽  
Weijie Zhang ◽  
Kuan-lin Wu ◽  
Ruchi Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Bone Tumor ◽  
Cancer Metastasis ◽  
Antibody Therapy ◽  
Breast Cancer Metastasis ◽  
Bone Lesions ◽  
Therapeutic Antibodies ◽  
Bone Targeting ◽  
Homing Peptide

Therapeutic antibodies have gone a long way toward realizing their clinical potential and have become very useful for treating a variety of pathologies. Despite the rapid evolution of therapeutic antibodies, their clinical efficacy in treatment of bone tumors has been hampered by the inadequate pharmacokinetics and poor bone tissue accessibility of these large macromolecules. Here, we show that engineering therapeutic antibodies to include bone-homing peptide sequences dramatically enhances their concentration in the bone metastatic niche, resulting in significantly reduced survival and progression of breast cancer bone metastases. To enhance the bone tumor-targeting ability of engineered antibodies, we introduced varying numbers of a bone-homing peptide into permissive internal sites of the anti-HER2 antibody trastuzumab. Compared to the unmodified antibody, the engineered bone-targeting antibodies have similar pharmacokinetics and in vitro cytotoxic activity against HER2-positive cancer cells, but exhibit improved bone tumor distribution in vivo. Accordingly, in xenograft models of breast cancer metastasis to bone sites, engineered antibodies with enhanced bone specificity exhibit increased inhibition of both initial bone metastases and secondary multi-organ metastases from bone lesions. Furthermore, this engineering strategy is also applied to prepare bone-targeting antibody-drug conjugates with enhanced therapeutic efficacy. These results demonstrate that adding bone-specific targeting to antibody therapy results in robust delivery of therapeutic antibodies to the bone tumor niche. This provides a powerful strategy for overcoming inadequate treatment of bone cancer and the development of potentially acquired resistance to therapy.

Whole body retention in relation to rate of bone resorption after intravenous bisphosphonate (pamidronate) in patients with breast cancer and bone metastases

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 881-881
Author(s):  
S. Cremers ◽  
L. Van Zuylen ◽  
H. Gelderblom ◽  
C. Seynaeve ◽  
H.-J. Guchelaar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Resorption ◽  
Bone Metastases ◽  
Whole Body ◽  
Body Retention ◽  
Intravenous Bisphosphonate
Sign in / Sign up

Export Citation Format

Share Document